GEN Exclusives

More »

GEN News Highlights

More »
Sep 19, 2006

Luminex and Exiqon to Work Together on microRNA Products

  • Luminex® and Exiqon signed an agreement to co-develop and commercialize microRNA products. Exiqon will develop and manufacture microRNA products on behalf of the Luminex Bioscience Group, based on Luminex’ xMAP® technology and Exiqon’s Locked Nucleic Acid (LNA™) technology.

    LNAs are a class of nucleotide analogue that binds strongly to RNA and DNA targets. By including LNAs in detection probes, it is possible to design specific high-affinity detection assays for small RNA targets like miRNAs, which otherwise would not be possible using standard DNA-based detection probes.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »